A landmark study reveals that children infected with COVID-19 generate fewer antibody varieties than adults. While less effective, this muted response may explain their milder symptoms and faster recovery.
The World Health Organization (WHO) highlights that older adults and those with pre-existing conditions face higher risks of severe COVID-19. Yet SARS-CoV-2 affects all ages, including children. Researchers from Columbia University Irving Medical Center, publishing in Nature Immunology on November 5, 2020, found children produce less diverse antibodies than adults. This limited variety correlates with reduced effectiveness but aligns with children's quicker recoveries and lower transmission rates.
Prior research links robust immune responses to severe disease. Children's subdued reactions may thus account for asymptomatic cases and ease of overcoming infection.
The study analyzed four COVID-19 patient cohorts: 19 non-hospitalized recovering adults; 13 hospitalized adults with respiratory distress; 16 hospitalized children with multisystem inflammatory syndrome (MIS-C, akin to Kawasaki disease); and 31 children with COVID-19, half asymptomatic.
Antibodies varied by group. Children primarily showed IgG antibodies, while symptomatic adults had multiple types, including more neutralizing ones.
Lead author Donna Farber links response intensity to infection severity: heavier viral loads demand broader immune activation. Children's systems excel at novel threats via abundant naive T cells, unlike adults' memory-driven responses, which may overreact to SARS-CoV-2.
Ultimately, COVID-19 appears as a routine infection for children, managed effectively by targeted antibodies and cells with fewer ACE2 receptors—the virus's entry points—compared to adults. Researchers urge caution due to the small sample sizes.
